PT - JOURNAL ARTICLE AU - Grossman, Aaron TI - Lead Exposure and Alzheimer’s Disease Mortality Among US Adults: NHANES Analysis from 1988-2008 AID - 10.1101/2024.07.20.24310751 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.20.24310751 4099 - http://medrxiv.org/content/early/2024/07/24/2024.07.20.24310751.short 4100 - http://medrxiv.org/content/early/2024/07/24/2024.07.20.24310751.full AB - Objective To investigate the association between blood lead level (BLL) and Alzheimer’s disease (AD) mortality.Design Prospective cohort study.Setting US National Health and Nutrition Examination Survey (NHANES) 1988-94 and 1999-2008.Participants 21,308 subjects aged 40 years and over with a BLL ≥1.0 µg/dL.Main outcome measures AD mortality from baseline until December 2019.Results AD was the underlying cause of death for 350 participants. In the fully adjusted model with a calendar effect variable, log-transformed BLL was inversely associated with AD mortality among all subjects (HR: 0.57 [95% CI, 0.46, 0.70]). A similar finding was evident when BLL was modeled as a categorical variable, with hazard ratios of 0.69 (95% CI: 0.54, 0.88), 0.56 (0.39, 0.80), 0.36 (0.19, 0.70), and 0.31 (0.14, 0.72) for 2.5-4.9 µg/dL, 5.0-7.4 µg/dL, 7.5-9.9 µg/dL, and ≥10 µg/dL, when compared to 1-2.4 µg/dL (p-trend < 0.0001). Restricted cubic spline analysis confirmed an inverse dose-response relationship between BLL and AD mortality.Conclusions Our study suggests an inverse association between lead exposure and AD mortality among US adults; however, the results should be interpreted with caution due to the observational nature of the study.What is already known on this topicStudies investigating the association of blood lead and Alzheimer’s disease are rare.Prior publications reported increased risk of Alzheimer’s disease mortality with exposure to lead, however, due to potential biases in these prior studies, it was critical to reassess the association between blood lead and Alzheimer’s disease mortality.What this study addsIn contrast to much of the existing literature on dementia, the findings from this study suggest that lead exposure reduces the risk of Alzheimer’s disease mortality and likely mitigates the development of Alzheimer’s disease itself.Prospective studies focused on blood lead and its association with the development or progression of Alzheimer’s disease are necessary to confirm the results.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study protocols for NHANES were approved by the National Center for Health Statistics (NCHS) Ethics Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNHANES datasets are publicly available.